Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis
Abstract: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects. A phase 3 trial (ALPINE) demonstrated improved efficacy and safety of zanubrutinib vs ibrutinib in pat...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2025-11-01
|
| Col·lecció: | Blood Neoplasia |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2950328025000858 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|